Koninklijke Philips N.V. operates as a health technology company in North America, Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, diagnostic X-ray, and imaging components as well as integrated clinical solutions; integrated interventional systems, including interventional diagnostic and therapeutic devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation, and patient management solutions; data, analytics, and actionable workflow solutions; and connected care informatics solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; male grooming and beauty products and solutions; and kitchen appliances, home care, and garment care products, as well as coffee machines. Koninklijke Philips N.V. has a partnership with openDoctor to deliver an integrated radiology patient engagement platform that leverages openDoctor's real-time online appointment scheduling services as part of its patient management solution; and a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
IPO Year:
Exchange: NYSE
Website: philips.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2025 | Sector Perform | RBC Capital Mkts | |
| 2/25/2025 | Neutral → Outperform | Exane BNP Paribas | |
| 2/20/2025 | Neutral → Buy | UBS | |
| 10/29/2024 | Underperform → Hold | Jefferies | |
| 5/13/2024 | Mkt Perform → Outperform | Bernstein | |
| 5/7/2024 | Underperform → Neutral | Exane BNP Paribas | |
| 4/30/2024 | Sell → Neutral | UBS | |
| 4/30/2024 | Underweight → Neutral | JP Morgan | |
| 2/7/2024 | Outperform → Underperform | Exane BNP Paribas | |
| 7/12/2023 | Buy | Goldman |
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
SD - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
20-F - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
RBC Capital Mkts initiated coverage of Philips with a rating of Sector Perform
Exane BNP Paribas upgraded Philips from Neutral to Outperform
Jefferies upgraded Philips from Underperform to Hold
Bernstein upgraded Philips from Mkt Perform to Outperform
Exane BNP Paribas upgraded Philips from Underperform to Neutral
JP Morgan upgraded Philips from Underweight to Neutral
Exane BNP Paribas downgraded Philips from Outperform to Underperform
Goldman initiated coverage of Philips with a rating of Buy
Fastest customizable press release news feed in the world
Two standout innovations recognized for excellence in body skincare and oral care Royal Philips (NYSE: PHG, AEX: PHIA) Two standout Philips innovations, Lumea IPL 9000 Series and Sonicare 6400, were named winners in Good Housekeeping's 2026 Beauty Awards. The full list of award winners can be found at goodhousekeeping.com/beautyawards2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602515443/en/Philips Sonicare 64000 Electric Toothbrush From the global no. 1 IPL brand1, Lumea IPL 9000 Series was recognized in the ‘skin-boosting body care' category as the ‘DIY Laser Hair Removal' product. Lumea IPL harnesses the power of
June 2, 2026 Philips receives FDA 510(k) clearance for Elevate Plus for EPIQ Elite and Affiniti, delivering AI advancements in general imaging ultrasound AI-powered workflow automation helps clinicians acquire high-quality reproducible images faster and with greater confidence Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced regulatory clearance in the USA of Elevate Plus, bringing advanced imaging and a suite of AI and automation capabilities to Philips EPIQ Elite and Affiniti, its flagship ultrasound systems. With CE Mark and 510(k) clearance, Elevate Plus helps standardize routine exams and reduce the need for re
June 2, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that the exchange ratio for the dividend for the year 2025 is 1 new common share for every 26.9341 existing common shares. This ratio was based on the volume-weighted average price of all traded common shares Koninklijke Philips N.V. at Euronext Amsterdam on May 27, 28 and 29, 2026, of EUR 22.8640 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 19,964,655 new common shares. Shareholders have been given the opportunity to make their choice between a dividend in shares or in cash. The aggreg
May 18, 2026 From imaging to AI-enabled guidance, Philips connects technologies into a unified workflow to improve efficiency, reduce radiation exposure and support procedural confidenceAmsterdam, the Netherlands – As cardiac procedures become more complex, interventional cardiologists must balance the need for precise imaging and decision-making with growing pressure to reduce radiation exposure for both patients and staff. At EuroPCR 2026 in Paris (May 19–22), Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, will showcase how advances in imaging, physiology and real-time guidance can help clinicians manage complexity while supporting safer, lower-dose procedures
May 18, 2026 Greater differentiation of clinical details through contrast-rich images with reduced background noiseFor coronary procedures, a new ultra-low dose protocol employs over 50% less X-ray radiation dose [1]First SmartIQ clinical pilot study published in JSCAI, further building on Philips' strong track record in evidence generation [2] Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced Philips SmartIQ, a breakthrough coronary imaging technology for its Azurion image-guided therapy. Developed in collaboration with leading cardiovascular centers, SmartIQ is designed to address one of the field's most fundam
May 18, 2026 Philips-led consortium selected through Karolinska University Hospital-led Region Stockholm tender to deliver advanced remote monitoring for complex patients Stockholm, Sweden - Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced that a consortium composed of Philips, Cuviva and Vingmed has been selected to support Region Stockholm's hospital-at-home initiative, enabling hospital-level care to be delivered in patients' homes across the region. The consortium was selected through a tender led by Karolinska University Hospital for an advanced remote-monitoring program serving patients with complex or chronic conditions. The up to eight-ye
May 8, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2026, including: Appointment of John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.Re-appointment of Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as members of the Supervisory Board, with effect from May 8, 2026.Re-appointment of Roy Jakobs (Dutch/German, 1974) as President/CEO and Chairman and member of the Board of Management, with effect from May 8, 2026.Discharge o
May 6, 2026Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable salesIncome from operations increased to EUR 241 millionAdjusted EBITA margin increased 40 basis points to 9.0%Operating cash flow of EUR 188 million, with free cash flow of EUR 28 million2026 outlook reiterated Roy Jakobs, CEO of Royal Philips:"We delivered a good start to 2026, with strong order intake growth at 6%, comparable sales growth of 4% and margin expansion of 40 basis points, reflecting disciplined execution against our plan in an uncertain macro-environment. Sales grew across segments and was led by North America and Europe. We are moving
April 23, 2026 Bridge Plus was designed for rare, life-threatening emergencies to help control bleeding during superior vena cava (SVC) tears, which occur in <0.5% of lead extraction procedures [1] but require immediate intervention Bridge Plus allows for rapid response when every second counts by deploying in under two minutes [2] and stopping up to 90% blood loss [3], helping stabilize patients with 30 minutes of hemostasis [4]Bridge Plus was built upon proven Bridge Occlusion Balloon technology, used in more than 50,000 U.S. procedures [5,*], with evidence showing improved survival when staged in advance [6,**] Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a globa
April 22, 2026 Clearances for Rembra CT, Rembra RT, and Areta RT enable high-throughput imaging at scale and elevate precision across the cancer care pathway Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Rembra platform of scanning systems, including Rembra CT, Rembra RT and Areta RT. The newly cleared systems are designed to help healthcare providers respond to growing demand for imaging and radiation therapy planning by helping to improve speed, efficiency, and access to high-quality imaging. As imaging volumes and clinical
Live Leadership Updates
May 8, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2026, including: Appointment of John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.Re-appointment of Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as members of the Supervisory Board, with effect from May 8, 2026.Re-appointment of Roy Jakobs (Dutch/German, 1974) as President/CEO and Chairman and member of the Board of Management, with effect from May 8, 2026.Discharge o
March 23, 2026 John DeFord proposed as new member of the Supervisory Board.Paul Stoffels, Herna Verhagen and Sanjay Poonen proposed for re-appointment as members of the Supervisory Board.Marc Harrison will step down from Philips' Supervisory Board after his second term.Roy Jakobs proposed for re-appointment as President/CEO and Chairman and member of the Board of Management, as previously announced. Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced a proposed Supervisory Board appointment and re-appointments, in addition to the previously announced proposal to re-appointment its President/CEO. The Supervisory Board wil
February 10, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced that Roy Jakobs is proposed to be re-appointed as its President/Chief Executive Officer and member of the Board of Management. The decision to propose the re-appointment of Roy Jakobs reflects the Supervisory Board's recognition of the progress made since 2022 and its confidence in his leadership as Philips enters the next phase of driving profitable growth. The proposal will be submitted for approval at the upcoming Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. "Roy Jakobs has demonstrated clear leadership, strong execution
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b
May 8, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2025, including: The re-appointment of Ms Indra Nooyi and Ms Chua Sock Koong as members of the Supervisory Board.The appointment of Mr Bob White as a new member of the Supervisory Board.The re-appointment of Mr Marnix van Ginneken as member of the Board of Management. The discharge of the members of the Board of Management, and of the members of the Supervisory Board.A full overview of the resolutions taken at the AGM 2025 can be found below. Feike Sijbesma, Chairman of Philips' Supervisory Board, sa
Mr David Pyott to retire from Philips' Supervisory Board after his third consecutive term.Mr Bob White proposed as new member of the Supervisory Board.Ms Indra Nooyi and Ms Chua Sock Koong proposed for reappointment as members of the Supervisory Board.Mr Marnix van Ginneken proposed for reappointment as member of Philips' Board of Management. February 19, 2025Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced proposed Supervisory Board appointments and reappointments, and a proposed Board of Management reappointment. Mr David Pyott (British/American, 1953) will retire from Philips' Supervisory Board at the end of the Annu
January 9, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the appointment of Jie Xue as Chief Business Leader Precision Diagnosis, and Özlem Fidanci as Chief of International Region, both effective January 1, 2025. Ms. Xue and Ms. Fidanci have joined Philips' Executive Committee and report directly to Roy Jakobs, CEO of Philips.Ms. Xue joins Philips from GE Healthcare to lead the Precision Diagnosis business that was temporarily led by Bert van Meurs, who will continue to lead Philips' Image Guided Therapy business. Ms. Xue and Mr. Van Meurs will be jointly responsible for the Diagnosis & Treatment segment. Ms. F
July 3, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA))), a global leader in health technology, today announced the appointment of Ms Ling Liu as the Chief Region Leader of Philips Greater China, effective immediately. Ms Liu is now a member of Philips' Executive Committee, reporting to Philips CEO Roy Jakobs. She succeeds Andy Ho, who has decided to retire after a long and successful career. Ms Liu and Mr Ho continue to work together to ensure a smooth handover. "Ling is a talented, trusted leader and I am delighted that she will join Philips' Executive Committee as the Chief Region Leader of Philips Greater China," said Roy Jakobs, CEO of Royal Philips. "Sh
May 7, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA))), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2024, including: The re-appointment of Chairman Feike Sijbesma and Peter Löscher as members of the Supervisory Board.The appointment of Benoît Ribadeau-Dumas as member of the Supervisory Board.The appointment of Charlotte Hanneman as member of the Board of Management, with effect from October 1, 2024.The discharge of the members of the Board of Management and members of the Supervisory Board.A full overview of the resolutions taken at the AGM 2024 can be found below.
February 28, 2024 Proposal to appoint Ms. Hanneman as member of Philips' Board of Management fulfilling the role of CFO per October 1, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA))), a global leader in health technology, today announced the proposal to appoint Charlotte Hanneman as member of the Board of Management, fulfilling the role of Chief Financial Officer (CFO), effective October 1, 2024. The proposal will be submitted to the Annual General Meeting of Shareholders (AGM), to be held on May 7, 2024. Ms. Hanneman will join Philips as a member of Philips' Executive Committee on June 1, 2024, to start her induction and transition into the
Live finance-specific insights
June 2, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that the exchange ratio for the dividend for the year 2025 is 1 new common share for every 26.9341 existing common shares. This ratio was based on the volume-weighted average price of all traded common shares Koninklijke Philips N.V. at Euronext Amsterdam on May 27, 28 and 29, 2026, of EUR 22.8640 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 19,964,655 new common shares. Shareholders have been given the opportunity to make their choice between a dividend in shares or in cash. The aggreg
May 6, 2026Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable salesIncome from operations increased to EUR 241 millionAdjusted EBITA margin increased 40 basis points to 9.0%Operating cash flow of EUR 188 million, with free cash flow of EUR 28 million2026 outlook reiterated Roy Jakobs, CEO of Royal Philips:"We delivered a good start to 2026, with strong order intake growth at 6%, comparable sales growth of 4% and margin expansion of 40 basis points, reflecting disciplined execution against our plan in an uncertain macro-environment. Sales grew across segments and was led by North America and Europe. We are moving
March 23, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. As previously announced, the agenda includes: Proposal to appoint John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.Proposals to re-appoint Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as members of the Supervisory Board, with effect from May 8, 2026.Proposal to re-appoint Roy Jakobs (Dutch/German, 1974) as President/CEO and Chairman and memb
Transaction establishes a scalable platform positioned for consolidation and growth in a $26B global emergency medical products market Emergency Care Holdings (ECH), a platform backed by Bridgefield Capital, today announced the completion of its acquisition of the Philips Emergency Care business from Koninklijke Philips N.V. (NYSE:PHG). The business will operate as Heartstream and continue to market select products under a Philips brand license. The acquisition represents the launch of ECH's global platform strategy focused on building a leading portfolio of emergency medical technology companies serving the pre-hospital care market. The emergency medical products sector exceeds $26 bil
November 4, 2025Q3 2025 Group Highlights Comparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable salesIncome from operations was EUR 330 millionAdjusted EBITA margin increased by 50 basis points to 12.3% of salesOperating cash flow of EUR 327 million, with a free cash flow of EUR 172 millionPhilips reiterates full-year 2025 outlook, with margin now expected at the upper end of the range Roy Jakobs, CEO of Royal Philips:"In this quarter we maintained our momentum, with AI-powered innovations and long-term partnerships making a real difference for patients and consumers. We drove strong order intake and accelerated sales growth, with sus
July 29, 2025 Q2 2025 Group Highlights Comparable order intake growth 6%Group sales EUR 4.3 billion, reflecting 1% increase in comparable salesIncome from operations EUR 400 millionAdjusted EBITA margin increased 130 bps to 12.4% of salesFree cash flow increased to EUR 230 millionPhilips increases full year 2025 outlook for Adjusted EBITA margin and free cash flow; reiterates comparable sales growth outlook Roy Jakobs, CEO of Royal Philips:"We are focused on driving profitable growth and delivering better care for more people. We built order intake growth momentum, supported by our recently launched AI-powered innovations. Our multi-year agreement with the Indonesian Ministry of Health re
June 5, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that the exchange ratio for the dividend for the year 2024 is 1 new common share for every 23.6353 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 30, June 2, and 3, 2025, of EUR 20.0600 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 22,980,748 new common shares. Shareholders have been given the opportunity to make their choice between a dividend in shares or (subject to certain conditions) in cash. The aggregate cash election
May 6, 2025Q1 2025 Group performance Group sales EUR 4.1 billion, reflecting a 2% decline in comparable sales growth mainly due to China; slightly ahead of company outlook due to Personal Health growth and royalty phasingComparable order intake increased 2% despite China declineIncome from operations increased to EUR 154 millionAdjusted EBITA margin declined 80 bps to 8.6% of sales, driven by sales phasingFree cash outflow of EUR 1,091 million included EUR 1,025 million payment for Philips Respironics recall-related medical monitoring and personal injury settlements in USUpdated full year 2025 outlook for Adjusted EBITA margin and free cash flow; sales outlook remains unchanged Roy Jakobs,
March 24, 2025Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)) today announced it has convened the Annual General Meeting of Shareholders (AGM) 2025 and published the agenda with explanatory notes.As previously announced, the agenda includes: Proposal to appoint Mr Bob White (American, 1962) as a new member of the Supervisory Board, with effect from May 8, 2025.Proposals to re-appoint Ms Indra Nooyi (American, 1955) and Ms Chua Sock Koong (Singaporean, 1957) as members of the Supervisory Board, with effect from May 8, 2025.Proposal to re-appoint Mr Marnix van Ginneken (Dutch, 1973) as a member of the Philips Board of Management, with effect from May 8, 2025. The agenda fu
February 19, 2025Full Year and Q4 Group performance highlights Sales of EUR 18.0 billion in 2024, comparable sales growth 1%; EUR 5.0 billion in Q4, comparable sales growth 1%, despite double-digit decline in ChinaComparable order intake increased 1% in 2024; up 2% in Q4, despite double-digit decline in ChinaIncome from operations was EUR 529 million in 2024; EUR 199 million in Q4Adjusted EBITA margin increased 90 basis points to 11.5% of sales in 2024; up 60 basis points to 13.5% in Q4Net cash flow from operating activities was EUR 1,569 million in 2024; EUR 1,459 million in Q4Free cash flow was EUR 906 million in 2024; EUR 1,285 million in Q4Finalized Philips Respironics recall-related me
This live feed shows all institutional transactions in real time.
SC 13D/A - KONINKLIJKE PHILIPS NV (0000313216) (Subject)
SC 13D/A - KONINKLIJKE PHILIPS NV (0000313216) (Subject)
SC 13D - KONINKLIJKE PHILIPS NV (0000313216) (Subject)
SC 13G/A - KONINKLIJKE PHILIPS NV (0000313216) (Subject)